Report Published: "Indonesia Pharmaceuticals & Healthcare Report Q3 2016"

The Indonesian medical landscape will see a larger presence of private healthcare providers over medium term. Underpinning this expansion is the robust prospects for the industry, with the introduction of a Coordination of Benefits scheme allowing patients to supplement their coverage under the universal healthcare programme with private insurance. In addition, private firms will be able to fill the gap in Indonesia's medical system which continues to suffer from the uneven distribution of resources. For pharmaceutical firms, this has the potential to facilitate a shift in patient flow away from public hospitals, which will require companies to adapt their marketing strategies.Headline Expenditure ProjectionsPharmaceuticals: IDR77.6trn (USD5.8bn) in 2015 to IDR85.6trn (USD6.0bn) in 2016; +10.2% growth in local currency terms and +3.3% in US dollar terms.

Full Report Details at
- http://www.fastmr.com/prod/1172840_indonesia_pharmaceuticals.aspx?afid=301

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- Brazil Pharmaceuticals & Healthcare Report Q3 2016
- Czech Republic Pharmaceuticals & Healthcare Report Q3 2016
- Bahrain Pharmaceuticals & Healthcare Report Q3 2016
- China Pharmaceuticals & Healthcare Report Q3 2016
- Egypt Pharmaceuticals & Healthcare Report Q3 2016